The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

The majority of ILD or pneumonitis events were low grade (grade 1 [n=17 ... “Bringing ENHERTU earlier in the treatment of HER2 positive metastatic breast cancer may represent an important ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

Enhertu (5.4mg/kg) is approved in more than 80 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH-) breast cancer who have received ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Tecsys Inc. , a global leader in supply chain management solutions, today announced the launch of TecsysIQtm, a cloud-native intelligence layer that helps healthcare organizations unify fragmented ...

Presented at ASCO 2025, new data from the DESTINY-Breast09 trial showed that Enhertu plus pertuzumab cut the risk of disease ...

In the ENHERTU arm, the majority of ILD or pneumonitis events were low grade (grade 1 [n=7 ... which represent the first time a HER2 directed medicine has demonstrated a survival benefit in a ...

There's a total of $698 billion worth of homes for sale in the U.S., up 20.3% from a year ago and the highest dollar amount ever, according to a new report from Redfin (redfin.com), the ...

The majority of ILD or pneumonitis events were low grade (grade 1 [n=17 ... metastatic diagnosis can delay disease progression.” “Bringing ENHERTU earlier in the treatment of HER2 positive metastatic ...